Fruquintinib Hepatic Impairment Study
NCT05216367 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2022-10-31
Summary
An Open-label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
Sponsors & Collaborators
-
Hutchmed
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-03-11
- Primary Completion
- 2022-10-25
- Completion
- 2022-10-25
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
NCT05684653 ·Status: UNKNOWN ·Phase: PHASE1
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
NCT03983161 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
NCT00692341 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
NCT01767688 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
NCT06442436 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
NCT07018492 ·Status: COMPLETED ·Phase: PHASE1
-
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
NCT04193436 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
NCT04056468 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment
NCT05856513 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276 ·Status: RECRUITING ·Phase: PHASE1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
NCT05610657 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
NCT00418626 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment
NCT04573582 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function
NCT04993404 ·Status: COMPLETED ·Phase: PHASE1
-
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
NCT03765671 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
NCT06390410 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
NCT04831944 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT05707390 ·Status: COMPLETED ·Phase: PHASE1
-
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
NCT02474537 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05517525 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
NCT01465412 ·Status: COMPLETED ·Phase: PHASE1